Dexrazoxane reduced clinical heart failure risk by 68% (RR 0.32; 95% CI 0.20-0.50) and statins reduced LVEF decline and cardiotoxicity rates (OR 0.41; 95% CI 0.27-0.63) in patients receiving anthracyclines; β-blockers reduced symptomatic heart failure risk (RR 0.29; 95% CI 0.10-0.85) and preserved LVEF with a mean difference of 3.44%; enalapril and ramipril had modest LVEF preservation effects; empagliflozin reduced cardiac dysfunction risk by 82% (RR 0.18; p=0.01) in high-risk breast cancer patients
Do pharmacologic cardioprotective therapies limit anthracycline-induced cardiotoxicity and preserve cardiac function?
Patients receiving anthracycline treatment
Pharmacologic cardioprotective therapies
Limiting anthracycline-induced cardiotoxicity and preserving cardiac function
Tailored, risk-based cardioprotective strategies guided by biomarkers and imaging show promise in limiting anthracycline-induced cardiotoxicity.
Several pharmacologic strategies offer potential benefit in limiting anthracycline-induced cardiotoxicity and preserving cardiac function. Tailored, risk-based approaches that incorporate cardioprotective therapies early in anthracycline treatment-guided by biomarkers and imaging-are most promising. Further large-scale randomised studies are required to establish optimal combinations and confirm long-term benefit.
Building similarity graph...
Analyzing shared references across papers
Loading...
Alotaibi et al. (Thu,) conducted a review in Patients treated with anthracycline-based chemotherapy including various cancers (breast, lymphoma, hematological malignancies), some with previous anthracycline exposure. Dexrazoxane reduced clinical heart failure risk by 68% (RR 0.32; 95% CI 0.20-0.50) and statins reduced LVEF decline and cardiotoxicity rates (OR 0.41; 95% CI 0.27-0.63) in patients receiving anthracyclines; β-blockers reduced symptomatic heart failure risk (RR 0.29; 95% CI 0.10-0.85) and preserved LVEF with a mean difference of 3.44%; enalapril and ramipril had modest LVEF preservation effects; empagliflozin reduced cardiac dysfunction risk by 82% (RR 0.18; p=0.01) in high-risk breast cancer patients.
www.synapsesocial.com/papers/69a7612fc6e9836116a2ee04 — DOI: https://doi.org/10.37616/2212-5043.1475
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Tariq Majed Alotaibi
Ahmad Mohammad Samman
Abdullah Abdulaziz Al Ghamdi
Journal of the Saudi Heart Association
King Abdulaziz Medical City
National Guard Health Affairs
Building similarity graph...
Analyzing shared references across papers
Loading...